The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and potentially reshape prescribing patterns in oncology and hematology.
Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...
Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...
There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...
Dr. Jessica Scott researches how exercise can prevent the decline in fitness often caused by cancer treatments. It may even change the biology of the cancer itself. Cancer patients may be surprised to ...
Oncology Media Relations oncology_media_relations@its.jnj.com Investor contact: Jessica Margevich investor-relations@its.jnj.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results